Shareholder Investigation of Tyme Technologies
Tyme Technologies Inc. (TYME) Accused of Distorting Data
According to the complaint, Tyme is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. On January 15, 2019, Tyme issued a press release touting the efficacy of SM-88 “in the treatment of multiple oncology indications, including breast and prostate, and pancreatic cancer.” On January 18, 2019, Tyme reported positive results from its Phase II study, stating that SM-88 “improves survival.” However, Tyme’s announcement merely compared survival data to historical controls. Analysts were quick to notice Tyme’s glaring design failure to include a control group in the Phase II study. A Motley Fool article went on to explain in detail the misleading picture as to the efficacy of SM-88 on pancreatic cancer. On this news, Tyme’s stock declined over 35% to close at $2.41 per share on January 18, 2019.
Tyme Technologies Inc. (TYME) Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.